🇺🇸 FDA

Company profile · Sponsor

PALVELLA

PALVELLA THERAPEUTICS, INC.

PVLA · NYSE pharma WAYNE, PA, USA
Pipeline
7
Drugs
0
Patents
8

Quick answer

PALVELLA (PVLA) is a pharma company. headquartered in WAYNE, PA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker PVLA
Exchange NYSE
Company type pharma
Headquarters WAYNE, PA, USA
SEC CIK 0001583648

Pipeline (7)

Search pipeline →

  1. PTX-022

    PALVELLA

    Pachyonychia Congenita

    phase 3 small molecule active

    3 trials

  2. QTORIN 3.9% Rapamycin Anhydrous Gel

    PALVELLA

    Microcystic Lymphatic Malformation

    phase 3 small molecule active

    1 trial

  3. QTORIN 3.9% rapamycin anhydrous gel

    PALVELLA

    Pachyonychia Congenita

    phase 3 small molecule completed

    1 trial

  4. PTX-022

    PALVELLA

    BCCs in Gorlin Syndrome Patients

    phase 2 small molecule completed

    1 trial

  5. PTX-022

    PALVELLA

    Microcystic Lymphatic Malformation

    phase 2 small molecule completed

    1 trial

  6. PTX-022

    PALVELLA

    Angiokeratomas

    phase 2 small molecule active

    1 trial

  7. QTORIN 3.9% rapamycin anhydrous gel

    PALVELLA

    Cutaneous Venous Malformations

    phase 2 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12329748

    Anhydrous compositions of mTOR inhibitors and methods of use

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12268673

    Anhydrous compositions of mTOR inhibitors and methods of use

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11679101

    Anhydrous compositions of mTOR inhibitors and methods of use

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11617742

    Methods of treating keratin hyperproliferation disorders using mTOR inhibitors

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11135204

    Anhydrous compositions of mTOR inhibitors and methods of use

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11000513

    Anhydrous compositions of mTOR inhibitors and methods of use

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10722499

    Anyhydrous compositions of mTOR inhibitors and methods of use

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10172789

    Compositions for transdermal delivery of mTOR inhibitors

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is PALVELLA?

PALVELLA (PVLA) is a pharma company. headquartered in WAYNE, PA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does PALVELLA sponsor?

We track 7 ClinicalTrials.gov-linked programs for PALVELLA, including PTX-022 and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does PALVELLA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.